tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics

Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics

Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Tyler Van Buren has given his Buy rating due to a combination of factors that highlight the promising potential of Maze Therapeutics, Inc.’s drug candidates. The company’s oral APOL1 inhibitor, MZE829, is positioned to address a significant portion of the over 1 million patients with APOL1-mediated kidney disease (AKD). With a potency approximately 100 times greater than Vertex’s inaxaplin, MZE829 has the potential to become a leading treatment in this space, with expected sales reaching around $2 billion by 2035 if it achieves the desired outcomes in its Phase II HORIZON trial.
Additionally, Maze Therapeutics’ MZE782, an oral SLC6A19 inhibitor, is a pioneering treatment targeting chronic kidney disease (CKD) and phenylketonuria (PKU). By mimicking the protective effects of a specific genetic variant, MZE782 offers a novel approach with a de-risked development path, bolstered by its superior potency compared to existing treatments. The potential market impact of MZE782 is substantial, with projected sales of $2.6 billion by 2035. These factors collectively underpin Van Buren’s optimistic outlook and Buy rating for Maze Therapeutics’ stock.

In another report released today, Guggenheim also initiated coverage with a Buy rating on the stock with a $19.00 price target.

Disclaimer & DisclosureReport an Issue

1